IDH1 and astrocytoma (excluding glioblastoma): In the cohort of the IDH-wt astrocytomas the TERT promoter was mutated in 28 of 41 analyzed patients (68.3%); EGFR amplification was detected in 23 out of 48 analyzed patients (47.9%); and nuclear ATRX loss was detected in 12 (9.6%) patients, while it was retained in 113 (90.4%).